142,228 Shares in Relay Therapeutics, Inc. $RLAY Bought by Sanctuary Advisors LLC

Key Points

• Sanctuary Advisors LLC bought a new stake of 142,228 shares in Relay Therapeutics during the fourth quarter, valued at about $1.20 million and representing roughly 0.08% of the company.
• Relay reported a recent quarterly miss (EPS -$0.41 vs. -$0.35 est.) and revenue of $3.0M (vs. $5.58M est.), trades in a 52-week range of $2.67–$17.32, and has a market cap near $2.49 billion.
• Analysts are broadly positive: MarketBeat lists an average rating of "Moderate Buy" with an average price target of $20.56, and several brokers recently raised their targets and ratings.

Sanctuary Advisors LLC bought a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 142,228 shares of the company's stock, valued at approximately $1,203,000. Sanctuary Advisors LLC owned about 0.08% of Relay Therapeutics as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Captrust Financial Advisors purchased a new position in shares of Relay Therapeutics in the 2nd quarter worth about $49,000. Cerity Partners LLC purchased a new position in shares of Relay Therapeutics during the 2nd quarter valued at about $51,000. Jump Financial LLC bought a new stake in Relay Therapeutics in the 2nd quarter worth approximately $53,000. Dynamic Technology Lab Private Ltd bought a new stake in Relay Therapeutics in the 1st quarter worth approximately $53,000. Finally, Abel Hall LLC purchased a new stake in Relay Therapeutics in the third quarter worth approximately $58,000. Hedge funds and other institutional investors own 96.98% of the company's stock.

Relay Therapeutics Stock Performance

NASDAQ:RLAY opened at $13.00 on Wednesday. Relay Therapeutics, Inc. has a fifty-two week low of $2.67 and a fifty-two week high of $17.32. The firm has a market cap of $2.49 billion, a PE ratio of -8.02 and a beta of 1.74. The business has a 50 day moving average price of $11.96 and a 200-day moving average price of $9.22.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.58 million. Research analysts predict that Relay Therapeutics, Inc. will post -1.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RLAY. Weiss Ratings reiterated a "sell (d-)" rating on shares of Relay Therapeutics in a research report on Wednesday, April 8th. Oppenheimer upped their price objective on shares of Relay Therapeutics from $14.00 to $18.00 and gave the company an "outperform" rating in a research note on Tuesday, April 28th. The Goldman Sachs Group increased their target price on shares of Relay Therapeutics from $13.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, April 28th. Barclays lifted their target price on shares of Relay Therapeutics from $17.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 8th. Finally, HC Wainwright boosted their price target on shares of Relay Therapeutics from $19.00 to $25.00 and gave the stock a "buy" rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $20.56.

Insider Transactions at Relay Therapeutics

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 1,800 shares of the business's stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $15.00, for a total value of $27,000.00. Following the transaction, the chief financial officer owned 213,867 shares in the company, valued at approximately $3,208,005. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 22,732 shares of company stock valued at $305,048. 4.32% of the stock is owned by company insiders.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

Want to see what other hedge funds are holding RLAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.